Hepion Pharmaceuticals
Yahoo Finance • 12 months ago
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - “These findings presented today at A... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
EDISON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alc... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of no... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
- Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to augment clinical trial in liver cancer - EDISON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:H... Full story
Yahoo Finance • last year
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
– Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues – – Superior effects of rencofilstat alone and in combination with pirfenidone and nintedanib – EDISON, N.J., Sept. 14, 2023 (GLOBE NEWSWI... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals Announces Management Changes
EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution – - Cyclophilin B inhibition confirmed as an important target for treatment of NAFLD/NASH -... Full story
Yahoo Finance • last year
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat
EDISON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fib... Full story
Yahoo Finance • 2 years ago
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibr... Full story
Yahoo Finance • 2 years ago
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fi... Full story
Yahoo Finance • 2 years ago
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fi... Full story
Yahoo Finance • 2 years ago
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fi... Full story
Yahoo Finance • 2 years ago
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress
EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fi... Full story
Yahoo Finance • 2 years ago
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
– Patent Covers 38 European Countries – – Rencofilstat’s Exclusivity May Extend into 2048 – EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused... Full story
Yahoo Finance • 2 years ago
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
EDISON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non... Full story
Yahoo Finance • 2 years ago
Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors
EDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non... Full story
Yahoo Finance • 2 years ago
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
EDISON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fib... Full story
